0001593968-23-000345.txt : 20230223 0001593968-23-000345.hdr.sgml : 20230223 20230223163723 ACCESSION NUMBER: 0001593968-23-000345 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230221 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ignelzi Troy A. CENTRAL INDEX KEY: 0001579829 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 23660311 MAIL ADDRESS: STREET 1: C/O ESPERION THERAPEUTICS, INC. STREET 2: 46701 COMMERCE CENTER DRIVE CITY: PLYMOUTH STATE: MI ZIP: 48170 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2023-02-21 0001771917 Karuna Therapeutics, Inc. KRTX 0001579829 Ignelzi Troy A. C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 false true false false Chief Financial Officer Common Stock 2023-02-21 4 M false 6000 9.2 A 36487 D Common Stock 2023-02-21 4 S false 6000 190.01 D 30487 D Option (right to buy) 9.20 2023-02-21 4 M false 6000 0 D 2029-03-21 Common Stock 6000 103726 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.96 to $190.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. /s/ Troy Ignelzi 2023-02-23